• Adia Nutrition (OTCQB: ADIA) has rebranded to Adia Med, reflecting a strategic shift toward medical and wellness solutions.
• The company cited ongoing clinical studies, a research pipeline, and distribution of stem cell and exosome products as core focus areas.
• Adia expects to trade under the Adia Med name once FINRA completes its review; the ticker symbol and CUSIP are set to remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606100915NEWSFILECNPR____20260610_300817_1) on June 10, 2026, and is solely responsible for the information contained therein.